A Phase 2/3 interventional study of Visugromab (CTL-002) and Placebo in Cancer-associated Cachexia, sponsored by CatalYm GmbH. Recruiting at 74 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-22.
Sponsored by CatalYm GmbH · Phase 2/3, Interventional, and Treatment
A study of how well and safely a new drug called visugromab works in people with certain kinds of cancer (including lung and bowel cancer) and unintended weight loss known as cachexia. The main questions it aims to answer are:
Participants will visit the hospital or clinic once every 4 weeks to receive visugromab or placebo via a drip into a vein and to undergo checkups and tests.
Exclusion Criteria:
Drug: Visugromab (CTL-002)
Drug: Visugromab (CTL-002)
Drug: Visugromab (CTL-002)
Drug: Placebo
High dose
IV infusion
Medium dose
Low dose
Change from baseline in body weight at 12 weeks
Time frame: 12 weeks
Change from baseline in appetite at 12 weeks
Measured on the 5-item anorexia subscale of the Functional Assessment of Anorexia/Cachexia Therapy instrument (minimum score 0, maximum 20; higher is better outcome)
Time frame: 12 weeks
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
CatalYm GmbH